These medications have received FDA approval for the treatment of BRAF-mutated melanoma.834,835 Research has demonstrated that medications aimed at BRAF/MEK in melanoma have the ability to boost the presentation of tumor antigens, elevate the accumulation and efficacy of effector T cells, and generate pro-inflammatory cytokines. This evidence concerns the gene BRAF and neoplasm.